Cardiovascular

FDA approves new hemophilia treatment

On June 6, the U.S. Food and Drug Administration (FDA) approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares